Disc Medicine (NASDAQ:IRON) Director Kevin Bitterman Sells 129 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director Kevin Bitterman sold 129 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $79.95, for a total transaction of $10,313.55. Following the transaction, the director directly owned 14,012 shares in the company, valued at approximately $1,120,259.40. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Bitterman also recently made the following trade(s):

• On Thursday, September 3rd, Kevin Bitterman sold 5,203 shares of Disc Medicine stock. The shares were sold at an average price of $79.98, for a total transaction of $416,135.94.
• On Wednesday, September 2nd, Kevin Bitterman sold 49,164 shares of Disc Medicine stock. The shares were sold at an average price of $80.17, for a total transaction of $3,941,477.88.

Disc Medicine Price Performance

IRON stock opened at $79.37 on Friday. The stock has a market capitalization of $3.05 billion, a PE ratio of -12.06 and a beta of 0.97. The company’s 50-day moving average is $77.67 and its 200-day moving average is $70.32. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Equities research analysts expect that Disc Medicine, Inc. will post -6.61 EPS for the current fiscal year.

Key Stories Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Wedbush raised its price target for Disc Medicine from $88 to $100 and maintained an “outperform” rating. The new target implies approximately 26% upside from the referenced $79.37 price, signaling continued analyst confidence in the company’s prospects. Benzinga analyst price target report
• Neutral Sentiment: Disc Medicine announced that management will participate in fireside chats at four upcoming investor conferences. These events could provide updates on the company’s hematology pipeline, but no new clinical or financial information was disclosed in the announcement. Disc Medicine investor conference announcement
• Negative Sentiment: Director Kevin Bitterman sold a combined 54,496 shares of Disc Medicine for approximately $4.37 million across transactions dated September 1–3. The sales reduced his position by roughly 80% overall, which may concern investors about insider conviction. However, the trades were executed under a pre-arranged Rule 10b5-1 plan, meaning they were scheduled in advance and do not necessarily reflect a current change in his outlook. SEC insider trading filing
• Negative Sentiment: Rosen Law Firm announced an investigation into potential securities claims involving allegations that Disc Medicine may have issued materially misleading business information. The announcement increases headline and litigation risk, although it does not establish wrongdoing or guarantee that a lawsuit will be filed. Rosen Law Firm investigation announcement

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. State of Wyoming purchased a new stake in Disc Medicine in the 2nd quarter valued at $25,000. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine during the 4th quarter worth $33,000. Allworth Financial LP bought a new stake in shares of Disc Medicine in the 2nd quarter worth $46,000. Nykredit A S purchased a new stake in shares of Disc Medicine in the second quarter valued at about $103,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Disc Medicine in the fourth quarter valued at about $141,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analyst Ratings Changes

IRON has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Disc Medicine in a report on Tuesday. HC Wainwright boosted their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Wedbush raised their price objective on shares of Disc Medicine from $88.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Wall Street Zen cut shares of Disc Medicine from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.70.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.